You are here

oncology

When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance

When FDA Requires Pediatric Studies for New Cancer Drug Submissions: New Draft Guidance

RAPS.org

pediatric cancer

Flag link:

Merck to acquire ArQule for $20 per share in cash or about $2.7 billion

Merck to acquire ArQule for $20 per share in cash or about $2.7 billion

Marketwatch

Flag link:

Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients

Why The Obsession With A Universal Cure For Cancer May Be Harming Research And Patients

Forbes

universal cancer vaccine

Flag link:

Lilly puts its cancer future in Loxo's hands

Lilly puts its cancer future in Loxo's hands

Biopharma Dive

Flag link:

Is Clovis Oncology Really a Buyout Candidate?

Is Clovis Oncology Really a Buyout Candidate?

Motley Fool

Clovis Oncology

Flag link:

Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio

Fierce Pharma

Flag link:

Teva forms academic R&D pacts to further biopharma strategy

Teva forms academic R&D pacts to further biopharma strategy

Fierce Biotech

Teva Pharmaceutical

Flag link:

AstraZeneca CEO: Closing In On A Cancer Cure

AstraZeneca CEO: Closing In On A Cancer Cure

Yahoo/Benzinga

Flag link:

Radius plans to cut loose oncology assets

Radius plans to cut loose oncology assets

Fierce Biotech

endocrine disorders

Flag link:

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Daiichi Sankyo pulls out of U.S. pain market amid oncology pivot, opioid scrutiny

Fierce Pharma

Flag link:

Biocept Files for $27 Million Offering

Biocept Files for $27 Million Offering

CP Wire

Flag link:

CMS proposes lifting restrictions on NGS cancer testing

CMS proposes lifting restrictions on NGS cancer testing

Biopharma Dive

next generation sequencing

Flag link:

Injection That Makes Colorectal Cancer ‘Glow’ During Surgery Enters Phase 3 Trial

Injection That Makes Colorectal Cancer ‘Glow’ During Surgery Enters Phase 3 Trial

Forbes

colorectal cancer

Flag link:

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

As Amgen zeroes in on cancer, neuroscience pipeline under the ax

Fierce Biotech

Flag link:

With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer

With Ex-Medivation Exec Hung at Helm, Nuvation Nabs $275M for Cancer

Xconomy

Flag link:

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field

Biopharma Dive

Ichnos Sciences

bispecific antibodies

Flag link:

Qiagen and Illumina in It for the Long Haul with 15-year Collaboration

Qiagen and Illumina in It for the Long Haul with 15-year Collaboration

Medical Devices and Diagnostics Industry

Flag link:

FDA leaders worry agency will lose out on talent in gene therapy, cancer fields

FDA leaders worry agency will lose out on talent in gene therapy, cancer fields

Biopharma Dive

Flag link:

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

Endpoints

Flag link:

Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit

Shiny, new and expensive: ESMO studies find new cancer drugs carry higher prices, add little benefit

Fierce Pharma

Flag link:

Pages